Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificLFTSF 95 Return-on-Tangible-Asset is 4.26% as of Dec. 2025, which is 57% below its 10-year median of 9.99. GuruFocus rates LFTSF with a GF Score™ of 95/100 and a GF Value™ of $0.35. The stock has 4 warning signs investors should review. Among 856 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 60.98% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. LifeTech Scientific's annualizedNet Income for the quarter that ended in Dec. 2025 was $26.3 Mil. LifeTech Scientific's average total tangible assets for the quarter that ended in Dec. 2025 was $618.8 Mil. Therefore, LifeTech Scientific's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 4.26%.
The historical rank and industry rank for LifeTech Scientific's Return-on-Tangible-Asset or its related term are showing as below:
LFTSF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.46 Med: 9.99 Max: 14.6
Current: 3.46
During the past 13 years, LifeTech Scientific's highest Return-on-Tangible-Asset was 14.60%. The lowest was 3.46%. And the median was 9.99%.
LFTSF's Return-on-Tangible-Asset is ranked better than 60.98% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs LFTSF: 3.46
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
LifeTech Scientific Return-on-Tangible-Asset Related Terms
LifeTech Scientific Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFTSF vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, LifeTech Scientific's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 4.26% mean?
LifeTech Scientific (LFTSF) has a Return-on-Tangible-Asset of 4.26% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LifeTech Scientific and its competitors. This is 57% below median its historical median of 9.99. Over the past decade, LifeTech Scientific's Return-on-Tangible-Asset has ranged from 3.46 to 14.60. According to the industry distribution chart, LifeTech Scientific ranks #334 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 39%.
Is LifeTech Scientific's Return-on-Tangible-Asset too high?
LifeTech Scientific's current Return-on-Tangible-Asset of 4.26% is 57% below median its 10-year median of 9.99. Over the past 10 years, this metric has ranged from a low of 3.46 to a high of 14.60. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. LifeTech Scientific's value of 4.26% is 616% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #334 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #334 out of 856 companies for Return-on-Tangible-Asset. This puts LifeTech Scientific in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.60. LifeTech Scientific's value of 4.26% is 616% above this benchmark. Historically, LifeTech Scientific's own Return-on-Tangible-Asset has ranged from 3.46 to 14.60 over the past decade. While the company's 10-year median is 9.99 vs. the industry median of 0.60, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Return-on-Tangible-Asset of 4.26% is 616% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Return-on-Tangible-Asset is 4.26%, which is 57% below median its own 10-year median of 9.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (LFTSF) has a current Return-on-Tangible-Asset of 4.26%. The stock's GF Value™ is $0.35, compared to a current price of $0.23 — trading 33.3% below its estimated fair value. The current Return-on-Tangible-Asset is 4.26%, which is 57% below median its 10-year median of 9.99 and 616% above the Medical Devices & Instruments industry median of 0.60. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For LifeTech Scientific (LFTSF), the current Return-on-Tangible-Asset is 4.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (LFTSF) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of $0.23 is trading 33.3% below its estimated GF Value™ of $0.35.
Key valuation signals for LFTSF:
Return-on-Tangible-Asset: 4.26% (57% below median its 10-year median of 9.99)
GF Value™: $0.35 vs. price of $0.23 (33.3% below fair value)
Industry Position: 616% above the Medical Devices & Instruments median (#334 of 856)
No single metric tells the full story. See the LFTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for LFTSF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFTSF has been successfully added to your 
